Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jonathan Treherne | M | 63 |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
Christopher Moyses | M | - |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | 9 years |
Howard Sheppard | M | - |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
T. Paul McCubbin | M | - |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Scopes
- Personal Network